AstraZeneca plc (NYSE:AZN) was the recipient of unusually large options trading on Wednesday. Investors purchased 8,259 put options on the stock. This represents an increase of 1,510% compared to the average volume of 513 put options.
Shares of AstraZeneca plc (NYSE:AZN) opened at 34.26 on Monday. The firm has a 50-day moving average price of $31.89 and a 200-day moving average price of $32.14. The company has a market capitalization of $86.75 billion, a PE ratio of 22.47 and a beta of 0.76. AstraZeneca plc has a 1-year low of $25.55 and a 1-year high of $35.60.
AstraZeneca plc (NYSE:AZN) last posted its quarterly earnings data on Thursday, July 27th. The company reported $0.87 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.46. The company had revenue of $5.05 billion for the quarter, compared to analyst estimates of $5.04 billion. AstraZeneca plc had a return on equity of 14.36% and a net margin of 8.83%. The business’s revenue was down 9.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.83 earnings per share. Equities analysts anticipate that AstraZeneca plc will post $1.91 earnings per share for the current year.
The firm also recently disclosed a None dividend, which was paid on Monday, September 11th. Shareholders of record on Friday, August 11th were paid a $0.44 dividend. This represents a yield of 2.98%. The ex-dividend date of this dividend was Wednesday, August 9th. AstraZeneca plc’s dividend payout ratio is currently 44.92%.
Institutional investors have recently bought and sold shares of the business. Meeder Asset Management Inc. acquired a new position in AstraZeneca plc in the second quarter worth $105,000. Salem Investment Counselors Inc. acquired a new position in AstraZeneca plc in the first quarter worth $107,000. Tower Research Capital LLC TRC boosted its stake in AstraZeneca plc by 3,782.0% in the first quarter. Tower Research Capital LLC TRC now owns 3,882 shares of the company’s stock worth $121,000 after purchasing an additional 3,782 shares in the last quarter. WFG Advisors LP boosted its stake in AstraZeneca plc by 36.0% in the second quarter. WFG Advisors LP now owns 3,716 shares of the company’s stock worth $127,000 after purchasing an additional 984 shares in the last quarter. Finally, Parallel Advisors LLC boosted its stake in AstraZeneca plc by 27.1% in the first quarter. Parallel Advisors LLC now owns 4,526 shares of the company’s stock worth $138,000 after purchasing an additional 964 shares in the last quarter. 14.17% of the stock is currently owned by institutional investors.
Several brokerages recently issued reports on AZN. BNP Paribas upgraded AstraZeneca plc from a “neutral” rating to an “outperform” rating in a research note on Monday, September 25th. Sanford C. Bernstein restated a “buy” rating on shares of AstraZeneca plc in a research note on Friday, September 22nd. Liberum Capital cut AstraZeneca plc from a “buy” rating to a “hold” rating in a research note on Thursday, September 14th. BMO Capital Markets began coverage on AstraZeneca plc in a research note on Wednesday, September 6th. They set an “outperform” rating and a $38.00 price objective on the stock. Finally, Natixis upgraded AstraZeneca plc from a “neutral” rating to a “buy” rating in a research note on Wednesday, September 6th. Four research analysts have rated the stock with a sell rating, eleven have given a hold rating and fourteen have assigned a buy rating to the company. AstraZeneca plc currently has a consensus rating of “Hold” and an average target price of $34.35.
ILLEGAL ACTIVITY NOTICE: This piece was reported by BBNS and is the sole property of of BBNS. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://baseballnewssource.com/markets/astrazeneca-plc-target-of-unusually-high-options-trading-azn/1700419.html.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with our FREE daily email newsletter.